Lemelson Capital

Lemelson Capital chief investment officer Emmanuel Lemelson recently increased his short position in Ligand Pharmaceuticals (NYSE: LGND) after its second quarter earnings report. “Any company whose EPS is down 76 percent year over year while its stock awards are up 100 percent and has...